
| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sale | 3,070 | $193.74 | $595K | 58.3K | View ↗ | |
| 2026-04-29 | Sheena Jonathan | Director | Sale | 3,071 | $196.42 | $603K | 255.7K | View ↗ | |
| 2026-04-27 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sale | 1,993 | $204.14 | $407K | 61.4K | View ↗ | |
| 2026-04-27 | Chapman Steven Leonard | Director & CEO AND PRESIDENT | Sale | 5,838 | $204.14 | $1.19M | 150.8K | View ↗ | |
| 2026-04-27 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sale | 917 | $204.39 | $187K | 187.5K | View ↗ |
No annual data found.
Should You Be Bullish on Natera (NTRA)?
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth
Is It Too Late To Consider Natera (NTRA) After Its Strong Multi Year Share Price Run?
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT